A specialized, discovery stage biotech, developing novel and best-in-class therapies to treat Oncology & Inflammation >>More
Track-record of over 40 programs in collaboration with some of the leading global Pharma partners >>More
With about 500 scientists, Aurigene has developed
deep expertise in various target classes >>More
Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
Curis and Aurigene Announce Collaboration, License and Option Agreement for Immuno-Oncology and Precision Oncology Targets...
Aurigene and Orion Announce Research, Collaboration and Option Agreement for BET Inhibitors